Drugs / Tetanus diphtheria toxoid
Trials 0
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03927222 Background | Sep 2019 → Feb 2023 | glioblastoma | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Terminated | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT00023504 Comparator | Jun 2002 → May 2017 | immunodeficiency disease | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tetanus-Diphtheria Toxoid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03927222 ↗ |
| Modality | Vaccine | “The vaccines include licensed and universally mandated diphtheria and tetanus toxoid” NCT00023504 ↗ |
| Route | Intramuscular | “intramuscularly into the deltoid muscle” NCT03927222 ↗ |